# Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

> **NCT06403761** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 158 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Cagrilintide
- **DRUG:** Placebo semaglutide
- **DRUG:** Placebo cagrilintide

## Key facts

- **NCT ID:** NCT06403761
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-06
- **Primary completion:** 2025-12-28
- **Final completion:** 2026-02-02
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06403761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06403761, "Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06403761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*